The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

XII.a

Left or biventricular dysfunction/failure

Publications

Gündoğan C, Erol Ö, Beyhan E, Gürsu RU, Çermik TF

Findings of congestive heart failure associated with sunitinib cardiotoxicity in (18)F-FDG PET/CT.

Revista espanola de medicina nuclear e imagen molecular. 2022;41(3):197-198

Skubitz KM

Cardiotoxicity Monitoring in Patients Treated with Tyrosine Kinase Inhibitors.

The oncologist. 2019;24(7):e600-e602

Boyle HJ, Chatté G, Rivoire M, Fléchon A

Lung toxicity in a patient treated with sunitinib.

The European respiratory journal. 2012;40(5):1300-3

Kirk R

Targeted therapies: Risk of heart failure with sunitinib.

Nature reviews. Clinical oncology. 2011;8(10):569

Richards CJ, Je Y, Schutz FA, Heng DY, Dallabrida SM, Moslehi JJ, Choueiri TK

Incidence and risk of congestive heart failure in patients with renal and nonrenal cell carcinoma treated with sunitinib.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2011;29(25):3450-6

Schmidinger M, Bojic A, Vogl UM, Lamm W, Zielinski CC

Management of cardiac adverse events occurring with sunitinib treatment.

Anticancer research. 2009;29(5):1627-9

Telli ML, Witteles RM, Fisher GA, Srinivas S

Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate.

Annals of oncology : official journal of the European Society for Medical Oncology. 2008;19(9):1613-8

Khakoo AY, Kassiotis CM, Tannir N, Plana JC, Halushka M, Bickford C, Trent J 2nd, Champion JC, Durand JB, Lenihan DJ

Heart failure associated with sunitinib malate: a multitargeted receptor tyrosine kinase inhibitor.

Cancer. 2008;112(11):2500-8

Machiels JP, Bletard N, Pirenne P, Jacquet L, Bonbled F, Duck L

Acute cardiac failure after sunitinib.

Annals of oncology : official journal of the European Society for Medical Oncology. 2008;19(3):597-9

Chu TF, Rupnick MA, Kerkela R, Dallabrida SM, Zurakowski D, Nguyen L, Woulfe K, Pravda E, Cassiola F, Desai J, George S, Morgan JA, Harris DM, Ismail NS, Chen JH, Schoen FJ, Van den Abbeele AD, Demetri GD, Force T, Chen MH

Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib.

Lancet (London, England). 2007;370(9604):2011-9